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Background: Alzheimer’s disease (AD), the commonest cause of dementia, represents a significant cost to UK society.
This analysis describes resource utilisation, costs and clinical outcomes in non-institutionalised patients with AD in the UK.
Methods: The GERAS prospective observational study assessed societal costs associated with AD for patients and
caregivers over 18 months, stratified according to baseline disease severity (mild, moderate, or moderately severe/severe
[MS/S]). All patients enrolled had an informal caregiver willing to participate in the study. Healthcare resource utilisation
was measured using the Resource Utilization in Dementia instrument, and 18-month costs estimated by applying unit
costs of services and products (2010 values). Total societal costs were calculated using an opportunity cost approach.
Results: Overall, 526 patients (200 mild, 180 moderate and 146 MS/S at baseline) were recruited from 24 UK centres.
Mini-Mental State Examination (MMSE) scores deteriorated most markedly in the MS/S patient group, with declines of 3.6
points in the mild group, 3.5 points in the moderate group and 4.7 points in the MS/S group; between-group differences
did not reach statistical significance. Patients with MS/S AD dementia at baseline were more likely to be institutionalised
(Kaplan–Meier probability 28% versus 9% in patients with mild AD dementia; p < 0.001 for difference across all severities)
and had a greater probability of death (Kaplan–Meier probability 15% versus 5%; p= 0.013) at 18 months. Greater disease
severity at baseline was also associated with concomitant increases in caregiver time and mean total societal costs. Total
societal costs of £43,560 over 18 months were estimated for the MS/S group, versus £25,865 for the mild group and
£30,905 for the moderate group (p < 0.001). Of these costs, over 50% were related to informal caregiver costs at each AD
dementia severity level.
Conclusions: This study demonstrated a mean deterioration in MMSE score over 18 months in patients with AD. It also
showed that AD is a costly disease, with costs increasing with disease severity, even when managed in the community:
informal caregiver costs represented the main contributor to societal costs.
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Alzheimer’s disease (AD) is the commonest cause of de-
mentia representing 60–80% of all cases of dementia
within Europe [1]. In the UK the Alzheimer’s Society has
estimated that AD represents up to 62% of all cases of
dementia [2]. Based on 2013 UK population data, the
Alzheimer’s Society estimated the total age-standardised
population prevalence of dementia to be 7% in those
aged 65 years and over, equivalent to one in every 14
people in that age group [2]. At this rate of prevalence,
approximately 850,000 individuals within the UK were
expected to be affected by dementia in 2015 [2].
There have been several studies that have looked at the
costs of dementia, most of which have used different meth-
odology. Overall, and not surprisingly, there is general
agreement that as the disease progresses the costs increase,
especially once institutionalisation is required [3, 4]. Fur-
thermore, informal care costs often form the majority of
total costs [5]. As many of these and other studies use dif-
ferent methodologies ranging from multi-country clinical
trial data and retrospective questionnaires, the robustness
of the data has been questioned [6] and the difficulties of
comparing studies has been highlighted [7].
Looking specifically at the UK, a recent analysis based on
a model using estimates of prevalence, percentage of home
versus care home usage, expenditure and quality of life, has
estimated that the total cost of dementia to UK society is
£26.3 billion per annum, representing an average annual
cost of £32,250 per person [2]. Of this, approximately £4.3
billion, or 16%, is spent on healthcare costs, £10.3 billion
(39%) on publicly and privately funded social care, and £0.1
billion (<1%) on other costs (including police time, re-
search, advocacy and support by the voluntary sector). The
remaining £11.6 billion (44%) represents the contribution
of those unpaid family and friends who become carers for
people with dementia [2]. The Alzheimer’s Society esti-
mates that 670,000 people within the UK act as the
primary, unpaid carer for an individual with dementia [8].
As the aforementioned studies lack robust, prospectively
collected, local data, we performed an analysis of real-world
UK data from the GERAS study. GERAS was a European
prospective observational study that assessed the outcomes
and societal costs associated with AD dementia for
community-dwelling patients and their caregivers over at
least 18 months. Patients were stratified according to their
dementia severity at baseline into mild, moderate and mod-
erately severe/severe disease groups, which broadly reflect
the guidelines from NICE. The study design and baseline
societal costs have been previously published [9]. The ob-
jective of the current paper is to describe the clinical out-
comes in the UK in terms of cognition, institutionalisation
and death, and to describe the costs seen in the different se-
verity groups over an 18-month time period. The value of
this study is its robustness, based on the prospective design,to gather national data on resource use and costs looking at
patients with mild, moderate and severe AD dementia and
the impact of this on their carers.
Methods
The GERAS study was an 18-month, multicentre, pro-
spective, non-interventional, observational cohort study
conducted in three European countries: the UK, France
and Germany [8]. The study was designed to reflect rou-
tine care in patients with AD dementia. All treatment
decisions were at the discretion of the treating physician,
and were made following standard care procedures dur-
ing the course of normal clinical practice; all treatments
were permissible.
The focus of the current analysis is on those data col-
lected from the UK. Inclusion criteria were community-
dwelling patients, aged at least 55 years, presenting within
the normal course of clinical care, diagnosed with probable
AD dementia according to the National Institute of Neuro-
logical and Communicative Disorders and Stroke and the
Alzheimer’s Disease and Related Disorders Association cri-
teria [10], with a Mini-Mental State Examination (MMSE)
score [11] of ≤26 points, and with an informal caregiver
who was willing to participate in the study and undertake
responsibility for the patient for at least 6 months of the
year. Enrolled patients were stratified according to baseline
disease severity as having mild (MMSE 21–26 points),
moderate (MMSE 15–20 points) or moderately severe/se-
vere AD dementia (MMSE ≤14 points). Ethical review
board approval of the study was obtained according to UK
regulations and written informed consent was obtained
from all participants or their caregivers.
Sample size for the GERAS study was calculated based
on the number of patients required to determine total
costs associated with resource use in each country with
sufficient precision, assuming 30% of patients would be
lost during 18 months of follow-up and an equal enrol-
ment of patients into the three AD dementia severity
groups. Based on these assumptions, a minimum of 200
patients per AD dementia severity group per country was
required for a 95% confidence interval ±10% of mean cost
at 18 months (total 600 patients from the UK).
Data were collected for patients and caregivers at
baseline, and at 6, 12 and 18 months during routine care
visits. Collected data included demographics, current medi-
cations, patient and caregiver health/social care resource
use (using the Resource Utilization in Dementia [RUD] in-
strument) [12], and MMSE score [11]. Other outcomes
data collected in the GERAS study (at baseline and
18 months only, not reported in this manuscript) include
the cognitive subscale of the Alzheimer’s Disease Assess-
ment Scale [13], patient functioning and behaviour (Alzhei-
mer’s Disease Co-operative Study Activities of Daily Living
Inventory [14, 15]), health-related quality of life (for both
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[16]), caregiver working status and caregiver burden (Zarit
Burden Interview [17]). The analysis reported here focuses
on specific clinical outcomes (change in cognition [MMSE
score], institutionalisation and death) and costs over the
18 months of the study.
Resource utilisation
The RUD instrument was used to measure healthcare re-
source utilisation by both patients and caregivers, and time
spent on informal care by caregivers [12]. The RUD instru-
ment, version RUD Complete 3.1, was administered by the
physician, and answered by the primary informal caregiver,
and the patient with AD when dementia severity permitted.
Resource use items collected included healthcare (out-
patient visits [including: general practitioner, geriatrician,
psychiatrist, neurologist, physiotherapist, occupational ther-
apist, social worker and psychologist visits], hospitalisations,
emergency room visits); community care services (district
nurse, home aid, food delivery, day care, transportation,
other); changes to patient living accommodation (perman-
ent, temporary, institutionalisation); caregiver working sta-
tus (working for pay, missing work days); and primary
caregiver time spent caring for the patient. Caregiver time
was calculated as the number of hours spent:
● assisting the patient with basic activities of daily
living (ADL) such as eating, bathing and dressing;
● assisting with instrumental ADL such as housework
and shopping; and
● supervising the patient as required to prevent
dangerous events such as risk of fire, and walking into
the road if alone.
Information relating to patient medications, out-of-
pocket expenses and additional financial support received,
such as whether the patient or caregiver receives money
from the government or an insurance company, was also
collected during the interview with the caregiver. Data were
collected from patients and caregivers at the baseline visit,
and then during routine care visits at 6, 12 and 18 months
(+/− 6 weeks [9]).
Cost estimation
Eighteen-month costs were estimated by applying unit
costs of services and products (2010 values) to the health
and social care resource use collected over the 18-month
follow-up period. For resource-use items, full details of
the unit costs applied and their sources have already been
reported (see the Supplementary Material in Wimo et al.
2013 [9]).
Total societal costs were calculated using an opportun-
ity cost approach taking into account productivity loss
for working caregivers and lost leisure time for non-working caregivers. Costs were calculated for the month
before each visit. Total societal costs were calculated by
adding patient healthcare costs (including medications,
hospitalisations and outpatient visits), patient social care
costs (including community care services, structural ad-
aptations to the home and extra financial support) and
caregiver informal care costs (including time spent giving
care and missing work). The number of hours for basic
and instrumental ADL were used to calculate caregiver
time, with 24 hours per day availability for total caregiver
time assumed, but time spent on supervision applied a
zero cost value. The unit cost of caregiver time for work-
ing caregivers was considered to be the value of lost pro-
duction time based on the national average wage per UK
population (a unit cost of £15.65 per hour at 2010 values;
see the Supplementary Material in Wimo et al. 2013 [9]);
for non-working caregivers, the unit cost of caregiver
time was considered to be the value of lost leisure time
based on 35% of the national average wage per UK
population. Mean costs are reported for each baseline se-
verity group, with bootstrapped 95% confidence intervals
of the means.
The following imputation rules were applied for
missing data: for institutionalised patients, mean
monthly costs from the last visit were used for the
period until institutionalisation, then monthly costs
for institutionalisation (standard monthly cost of care
with zero other costs) were used from institutionalisa-
tion up to 18 months; for patients who died, last ob-
servation carried forward was used, such that costs
from the last known visit were extrapolated up to the
date of death (no costs after death were computed).
For those patients with other reasons for discontinu-
ation, multiple imputation regression method [18]
stratified by MMSE group was performed on missing
costs. The list of factors used in the multiple imput-
ation procedure was selected from those identified by
Dodel et al. [19]. In addition to the above-described
base case approach, three sensitivity analyses of costs
were performed applying alternative imputation rules
for missing data.
Statistical analyses
Demographics and baseline characteristics were sum-
marised using descriptive statistics and were based on
non-missing observations. In common with other
clinical studies in AD [20–23], the change in MMSE
score from baseline to 18 months was analysed using
a mixed-model repeated measures analysis; this ap-
proach provides robust inference even in the presence
of missing data. The model for the fixed effects in-
cluded terms for AD dementia severity at baseline
(classified as mild, moderate or moderately severe/se-
vere), visit, and AD dementia severity at baseline-by-
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ther than absolute scores) were being analysed, the
inclusion of baseline AD dementia severity level as a
covariate negated the need for including baseline
demographics in the model.
The Kaplan–Meier method was used to describe the
probabilities of institutionalisation and death, and dif-
ferences across baseline AD dementia severity groups
for these time-to-event endpoints were tested using
the log-rank test. Descriptive statistics were used to
describe baseline variables and discontinuations.
Comparisons across baseline AD dementia severity
groups were made using analysis of variance (ANOVA)
for continuous variables or the Cochran–Mantel–Haens-
zel test for categorical variables.
All analyses were performed using SAS version 9.2
(SAS Institute, Cary, NC, USA).Results
A total of 526 patients (200 mild, 180 moderate and
146 moderately severe/severe AD dementia) were re-
cruited from 24 centres across the UK; baseline pa-
tient characteristics are shown in Table 1. Patient
numbers at 18 months, when stratified according to
baseline severity, are shown in Fig. 1. By the 18-
month visit, 185 patients (35.2%) had discontinued
the study due to institutionalisation (n = 94; 50.8% of
discontinuations), death (n = 40; 21.6%) or other rea-
sons (n = 51; 27.6%) e.g., lost to follow up, patientTable 1 Patient demographics at baseline for the overall population




Mean age in years [SD] 78.9 [6.7] 78.
Gender, n female [%] 100 [50.0] 94
MMSE score, mean [SD] 23.1 [1.6] 17.
Mean time since diagnosis in years [SD] 1.8 [2.1] 2.0
Caregiver lives with patient, n [%] 156 [78.0] 129
Caregiver is spouse, n [%] 144 [72.0] 113
Caregiver mean age in years [SD] 69.4 [11.70] 66.
Caregiver gender, n female [%] 129 [64.5] 120
AD medication use, n [%]
No AD medication 31 [15.5] 29
Acetylcholinesterase inhibitor monotherapy 167 [83.5] 144
Memantine monotherapy 1 [0.5] 5 [
Acetylcholinesterase inhibitor + memantine 1 [0.5] 2 [
Percentages are based on the number of respondents (<1.0% missing)
AD Alzheimer’s disease, ANOVA analysis of variance, MMSE Mini-Mental State Examin
standard deviation
aANOVA p-value for continuous variables, Cochran–Mantel–Haenszel p-value for cat
bP-value relates to the relationship of the caregiver to the patientdecision. Proportions of patients discontinuing in-
creased with increasing baseline severity of AD de-
mentia (Fig. 1).Clinical outcomes (MMSE)
Mean MMSE scores
Over the 18-month duration of the GERAS study, a statisti-
cally significant deterioration in mean MMSE scores was
observed (p < 0.001), which was most marked in the mod-
erately severe/severe patient group (Fig. 2); declines in
MMSE score were 3.6 points in the mild group, 3.5 points
in the moderate group and 4.7 points in the moderately se-
vere/severe group. However, differences in MMSE score
changes between the groups did not reach statistical signifi-
cance (p = 0.24).Severity level transitions
A total of 330 patients had a MMSE score at 18 months
(64.8%). Among patients assessed as having mild disease
at baseline, 43.5% remained with mild disease, 36.7%
transitioned from mild to moderate disease, 11.6% tran-
sitioned from mild to moderately severe/severe disease,
and 8.2% had an MMSE score of >26. For those with
moderate disease at baseline, 6.1% had scores indicating
mild disease, 52.6% still had moderate disease and 41.2%
progressed to moderately severe/severe disease. Among
patients with moderately severe/severe disease at base-








8 [8.1] 77.6 [8.7] 78.5 [7.8] 0.238
[52.2] 91 [62.3] 285 [54.2] 0.061
8 [1.7] 8.7 [4.5] 17.3 [6.4] N/A
[1.9] 3.1 [2.2] 2.2 [2.1] <0.001
[71.7] 122 [83.6] 407 [77.4] 0.037
[62.8] 98 [67.1] 355 [67.5] 0.043b
9 [11.77] 68.7 [12.21] 68.3 [11.90] 0.099
[66.7] 76 [52.1] 325 [61.8] 0.016
0.012
[16.1] 19 [13.1] 79 [15.0] −
[80.0] 113 [77.9] 424 [80.8] −
2.8] 5 [3.4] 11 [2.1] −
1.1] 8 [5.5] 11 [2.1] −
ation, MS/S moderately severe/severe, N/A not applicable, SD
egorical variables between AD dementia severity groups
Fig. 1 Patient disposition at 18 months according to baseline AD dementia severity group AD Alzheimer’s disease, MS/S moderately severe/severe
Fig. 2 Change in MMSE score from baseline to 18 months stratified according to baseline AD dementia severity. AD, Alzheimer’s disease, MMSE
Mini-Mental State Examination. Data are presented as least square means with 95% confidence intervals from mixed-model repeated measures
analysis adjusted for baseline MMSE score. Change-from-baseline data missing for 0–9.0, 1–11.0 and 3.0–12.0% of patients across AD dementia
severity groups at 6, 12 and 18 months, respectively
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severe disease (Fig. 3).
Probability of institutionalisation
There was a significant difference in the probability of insti-
tutionalisation between the three AD dementia severity
groups (p < 0.001 for overall difference between severities).
Patients with moderately severe/severe AD dementia at
baseline were more likely to be institutionalised at
18 months (Kaplan–Meier probability estimate, 28.0%) than
those with mild AD dementia (9.0%) at baseline (Table 2).
Overall, the probability of being institutionalised by
18 months was 17.2%.
Probability of death
There were also significant differences between the three
severity groups in terms of probability of death (p = 0.013).
At 18 months, the probability of death in those with mod-
erately severe/severe AD dementia at baseline was greater
than in those with mild AD dementia (14.9% compared
with 5.3%). The probability of death at 18 months overall
was 8.2% (Table 2).Caregiver time
At baseline, AD dementia severity was associated with
increased mean total caregiver time (p < 0.001) and with
increases in any of its components: time spent on basicFig. 3 AD dementia status at 18 months stratified according to baseline se
Percentages and patient numbers (n) shown exclude deaths and institutionor instrumental ADL or supervision (Fig. 4). Over the
18 months of the GERAS study, caregiver time spent on
basic and instrumental ADL, together with time re-
quired for supervision, increased on average in all sever-
ity groups (Fig. 4). This increase from baseline was not
significantly different across baseline AD dementia se-
verity groups for any component of caregiver time or for
overall caregiver time at 18 months.
Societal costs
The estimated mean total societal costs per patient over
the 18-month duration of the study increased according
to AD dementia severity, with total costs (bootstrapped
95% confidence intervals) of £43,560 (£39,059–£48,481)
in patients with moderately severe/severe AD dementia
compared with £25,865 (£23,444–£28,538) in those with
mild and £30,905 (£28,539–£33,371) in those with mod-
erate AD dementia (p < 0.001; Fig. 5). The largest com-
ponent was the costs for caregiver informal care, which
represented over 50% of costs for each AD dementia se-
verity group.
As with total societal costs, there was a significant in-
crease in caregiver informal care costs and patient social
care costs associated with increases in AD dementia se-
verity (p < 0.001), but patient healthcare costs were not
significantly increased (p = 0.624). The results of the sen-
sitivity analyses confirmed these base case findings (data
not shown).verity. AD, Alzheimer’s disease, MMSE Mini-Mental State Examination.
alised patients
Table 2 Probability of institutionalisation, or death, during the 18-month GERAS study, according to baseline AD dementia severity
Mild AD dementia Moderate AD dementia MS/S AD dementia Overall
Probability of being institutionalised at 18 months, % 9.0 17.9 28.0 17.2
95% CI 5.6; 14.3 12.7; 24.7 21.0; 36.7 14.1; 21.0
Probability of death at 18 months, % 5.3 6.5 14.9 8.2
95% CI 2.9; 9.6 3.5; 11.7 9.6; 22.7 6.0; 11.1
The Kaplan–Meier method was used to calculate probabilities and their associated 95% CIs
AD Alzheimer’s disease, CI confidence interval, MS/S moderately severe/severe
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This analysis from the GERAS observational study pro-
vides new information on clinical outcomes and societal
costs associated with AD dementia in community-
dwelling patients in the UK using prospective data. Deteri-
oration in mean MMSE score over 18 months occurred at
a similar rate in the mild and moderate AD dementia se-
verity groups, with both showing a mean decrease of
around 3.5 points over 18 months, and was greatest in the
moderately severe/severe group (4.7 point decrease), al-
though differences in MMSE score changes between the
groups were not statistically significant. The probability of
progression to institutionalisation or death increased in
line with increases in baseline AD dementia severity.
Historically, the deterioration in MMSE score over time
has been described as non-linear [24], as supported by aFig. 4 Caregiver time for activities of daily living stratified by baseline AD d
MS/S moderately severe/severe. All values are based on data provided for t
overall monthly caregiver time; this is not the sum of the three componen
month. The n value is the number of respondents (0–9.0% missing). SD ran
AD dementia severities were as follows: Overall time, 192–263 h; Supervisiorecently published, 18-month, randomised clinical trial in
mild and moderate AD dementia [21]. In that study,
MMSE scores in the mild and moderate groups receiving
placebo decreased by an average of 2.4 and 5.8 points, re-
spectively, over the 18-month period [21], and a similar de-
cline in cognitive function was also seen in the same
timeframe in a further study [22]. The results in our obser-
vational study did not demonstrate this trend. This dispar-
ity could be attributed to differences in study methodology,
as randomised clinical trials are protocol-driven and pa-
tients are encouraged to stay within the trial; the greater pa-
tient retention rate observed in randomised clinical trials
may mean that more information on patients’ MMSE
scores over time is available. This difference in retention
rates will be exaggerated by the inclusion of patients with
more severe AD dementia within the GERAS study, whereementia severity. AD Alzheimer’s disease, ADL activities of daily living,
he last month before each visit. The value beside each bar is the mean
ts of caregiver time because caregiver time was capped at 720 h/
ges observed across each individual endpoint at all time points and
n time, 120–269 h; Basic ADL, 59–138 h; Instrumental ADL, 83–150 h
Fig. 5 Estimated mean total societal costs of AD stratified according to baseline AD dementia severity, per patient. AD Alzheimer’s disease,
ANOVA analysis of variance, MS/S moderately severe/severe. An opportunity cost approach was used for working and non-working caregivers;
supervision time was excluded from caregiver time. Missing data were imputed at both the total societal cost and cost item level. The value
above each column gives the mean total 18-month overall societal costs. This value is not the sum of the individual components as total societal
costs were imputed separately from the imputation method used on the three cost components. *ANOVA p-value for comparison between AD
dementia severity groups for total societal costs
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known that the baseline demographics are different be-
tween the populations in these two types of studies.
In our analysis, 8.2% of patients with mild AD dementia
at baseline had an MMSE score >26 at 18 months, while
48.3% of patients demonstrated a decline in MMSE score,
with 11.6% transitioning from the mild to the moderately
severe/severe group. Although variability between individ-
ual patients is often observed [25], some of these patients
may not have had Alzheimer’s disease.
Our study demonstrated that patients with more severe
dementia had a higher rate of institutionalisation and were
more likely to die than those with less severe AD dementia.
This is not surprising, and is consistent with the findings of
a study conducted in 779 dementia patients recruited at
nine memory centres, which demonstrated that a shorter
time to institutionalisation was associated with lower cogni-
tive ability, lower functional ability and more neuropsychi-
atric symptoms at baseline [26]. The greater the degree of
deterioration in cognitive ability noted during the first
3 months of this study, the shorter the observed time to
institutionalisation [26].
Consistent with baseline results [9], total societal costs in-
creased with increasing baseline AD dementia severity, and
caregiver informal care costs accounted for the highest pro-
portion of the component costs in GERAS at all levels ofseverity. This latter finding potentially represents a large
cost saving in terms of formal healthcare costs. A UK sur-
vey of caregivers of people with dementia found that many
caregivers do not receive the support they need from health
and care services, with key services such as home support
for personal care, day care and provision of respite/time off
from caring being either not offered or funded privately
[27]. Carers should be provided with comprehensive sup-
port, including assistance with day-to-day caring, emotional
support and regular, planned access to respite to support
their own quality of life [4]. This is especially true given pre-
vious publications demonstrating an increase in caregiver
burden with severity of AD dementia [28, 29].
The costs of Alzheimer’s disease to society observed in
our study are substantial and were estimated to be ap-
proximately £26,000 for mild severity, £31,000 for moder-
ate severity and £44,000 for the moderately severe/severe
group per patient over an 18-month period. This trans-
lates to annual costs per patient of approximately £17,000
per year for mild, £21,000 for moderate and £29,000 for
moderate/severe severity groups. These are comparable to
the community figures calculated from the Alzheimer’s
Society which have been rounded to annual rates per pa-
tient of £26,000 for mild, £43,000 for moderate and
£55,000 for severe cases supporting the robustness of the
data despite some methodological differences [1].
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Strengths of this study include that it was a large, prospect-
ive, observational study with a well-defined patient cohort,
which collected longitudinal data over an 18-month period
and assessed patients within the community across a range
of disease severities. This study design would be expected
to generate more reliable estimates of clinical outcomes, re-
source use and costs than either small cross-sectional stud-
ies [4, 30, 31] or retrospective database analyses, which may
be susceptible to bias in data selection [32, 33].
The study also has limitations. Given the recruitment of
patients principally from secondary care sites, it is possible
that the sample is not truly representative of the overall
AD dementia patient population. In addition, caregivers
and participants were required to be sufficiently fit to par-
ticipate in the study, which may represent a selection bias
across all severities. It can also be challenging to make
comparisons between studies due to different cost estima-
tion methods, making analysis and interpretation of cost
and resource data more difficult. Moreover, the 18-month
duration of this study is still relatively short for accurately
determining correlations between AD dementia severity
and rate of cognitive decline or the probability of institu-
tionalisation or death.
Conclusions
This observational study demonstrated a rate of deterior-
ation in cognition of at least 3.5 points on the MMSE scale
over the 18-month study period across all patient groups
stratified according to baseline AD dementia severity. In-
creasing severity of disease was associated with increased
patient institutionalisation and death, together with in-
creased total societal costs. Our results show that even
when managed within the community, AD dementia is a
costly disease, with costs associated with informal care-
givers representing the main contributing factor to societal
costs. Given the greater costs associated with increasing se-
verity of disease, any treatment that could help slow disease
progression may have a significant impact on the costs of
community-based care for patients with AD dementia.
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